CD8A and neoplasm: Furthermore, the maintenance of tumor-specific CD8+ T cell expansion was predictive of better survival outcomes compared to those with lower levels of tumor-specific CD8+ T cells, suggesting that the durable increase in tumor-specific T cells systemically in response to nivolumab therapy may rely on the presence of the primary tumor during treatment.